2,768,520 Shares in Septerna, Inc. (NASDAQ:SEPN) Acquired by Samsara BioCapital LLC

Samsara BioCapital LLC acquired a new stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,768,520 shares of the company's stock, valued at approximately $63,399,000. Septerna accounts for 8.6% of Samsara BioCapital LLC's investment portfolio, making the stock its 3rd largest holding. Samsara BioCapital LLC owned approximately 6.24% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Septerna during the 4th quarter worth approximately $185,000. Rhumbline Advisers acquired a new position in shares of Septerna during the fourth quarter worth approximately $458,000. New York State Common Retirement Fund bought a new position in shares of Septerna in the 4th quarter worth $32,000. Bank of New York Mellon Corp acquired a new stake in Septerna in the 4th quarter valued at $872,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Septerna during the fourth quarter worth $3,197,000.

Septerna Price Performance

Shares of NASDAQ SEPN traded up $0.34 during trading on Friday, hitting $7.48. The stock had a trading volume of 202,765 shares, compared to its average volume of 420,448. The company's fifty day moving average price is $6.10. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to analysts' expectations of $0.13 million. On average, research analysts anticipate that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Ratings Changes

SEPN has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $50.00 price objective on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company cut their price target on Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, March 28th.

Insiders Place Their Bets

In related news, CFO Gil M. Labrucherie purchased 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $5.85 per share, with a total value of $29,250.00. Following the acquisition, the chief financial officer now owns 30,000 shares of the company's stock, valued at $175,500. This trade represents a 20.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Alan Ezekowitz acquired 7,491 shares of Septerna stock in a transaction on Tuesday, March 4th. The shares were purchased at an average cost of $6.35 per share, with a total value of $47,567.85. Following the completion of the acquisition, the director now owns 24,911 shares of the company's stock, valued at $158,184.85. This trade represents a 43.00 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 74,346 shares of company stock valued at $439,670.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.